New established cell lines from undifferentiated pleomorphic sarcoma for in vivo study

BMB Rep. 2023 Apr;56(4):258-264. doi: 10.5483/BMBRep.2022-0209.

Abstract

As a high-grade soft-tissue sarcoma (STS), undifferentiated pleomorphic sarcoma (UPS) is highly recurrent and malignant. UPS is categorized as a tumor of uncertain differentiation and has few options for treatment due to its lack of targetable genetic alterations. There are also few cell lines that provide a representative model for UPS, leading to a dearth of experimental research. Here, we established and characterized new cell lines derived from two recurrent UPS tissues. Cells were obtained from UPS tissues by mincing, followed by extraction or dissociation using enzymes and culture in a standard culture environment. Cells were maintained for several months without artificial treatment, and some cell clones were found to be tumorigenic in an immunodeficient mouse model. Interestingly, some cells formed tumors in vivo when injected after aggregation in a non-adherent culture system for 24 h. The tissues from in vivo study and tissues from patients shared common histological characteristics. Pathways related to the cell cycle, such as DNA replication, were enriched in both cell clones. Pathways related to cell-cell adhesion and cell-cell signaling were also enriched, suggesting a role of the mesenchymal-to-epithelial transition for tumorigenicity in vivo. These new UPS cell lines may facilitate research to identify therapeutic strategies for UPS. [BMB Reports 2023; 56(4): 258-264].

Publication types

  • News

MeSH terms

  • Animals
  • Cell Differentiation
  • Cell Line, Tumor
  • Mice
  • Sarcoma* / drug therapy
  • Sarcoma* / genetics
  • Sarcoma* / pathology

Grants and funding

ACKNOWLEDGEMENTS This work was supported in part by National Cancer Center Grant NCC-2110521 (to H.J.Y.), NCC-2110330 (to H.J.Y.), 1810865 (to H.J.Y.) and National Research Foundation of Korea Grant funded by the Korea Government (MSIP, South Korea) (NRF-2021R1A2C2014147 to H.J.Y.).